Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

Authors: Kulbhushan Tikoo, Parveen Kumar, Jeena Gupta

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Antineoplastic drug cisplatin remains the drug of choice for various solid tumours including breast cancer. But dose dependent nephrotoxicity is the major drawback in majority of platinum based chemotherapy regimens. Recent reports have shown that inflammatory pathways are the main offender for cisplatin induced nephrotoxicity. The present study was undertaken to assess the effect of rosiglitazone, a PPARγ agonist and an anti-inflammatory agent, on cisplatin induced nephrotoxicity, and its anticancer activity in DMBA induced breast cancer rats.

Methods

Mammary tumours were induced in female Sprague-Dawley rats by feeding orally with dimethylbenz [a]anthracene (DMBA) (60 mg/kg). Cisplatin induced nephropathy was assessed by measurements of blood urea nitrogen, albumin and creatinine levels. Posttranslational modifications of histone H3, mitogen-activated protein (MAP) kinase p38 expression and PPAR-γ expression were examined by western blotting.

Results

Our data shows involvement of TNF-α in preventing cisplatin induced nephrotoxicity by rosiglitazone. Rosiglitazone pre-treatment to cisplatin increases the expression of p38, PPAR-γ in mammary tumours and shows maximum tumour reduction. Furthermore, cisplatin induced changes in histone acetylation, phosphorylation and methylation of histone H3 in mammary tumours was ameliorated by pre-treatment of rosiglitazone. Suggesting, PPAR-γ directly or indirectly alters aberrant gene expression in mammary tumours by changing histone modifications.

Conclusion

To best of our knowledge this is the first report which shows that pre-treatment of rosiglitazone synergizes the anticancer activity of cisplatin and minimizes cisplatin induced nephrotoxicity in DMBA induced breast cancer.
Appendix
Available only for authorised users
Literature
1.
Jarrar MH, Baranova A: PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. Journal of cellular and molecular medicine. 2007, 11 (1): 71-87. 10.1111/j.1582-4934.2007.00003.x.CrossRefPubMedPubMedCentral
2.
Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB: A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer research. 1999, 59 (22): 5671-5673.PubMed
3.
Bogdanovic G, Kojic V, Srdic T, Jakimov D, Djuran MI, Bugarcic ZD, Baltic M, Baltic VV: Growth Effects of Some Platinum(II) Complexes with Sulfur-Containing Carrier Ligands on MCF7 Human Breast Cancer Cell Line upon Simultaneous Administration with Taxol. Metal-based drugs. 2002, 9 (1–2): 33-43. 10.1155/MBD.2002.33.CrossRefPubMedPubMedCentral
4.
Li S, Gokden N, Okusa MD, Bhatt R, Portilla D: Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. American journal of physiology. 2005, 289 (2): F469-480.PubMed
5.
Ali BH, Al Moundhri MS: Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 2006, 44 (8): 1173-1183. 10.1016/j.fct.2006.01.013.CrossRefPubMed
6.
Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV: Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol. 2005, 16 (3): 697-702. 10.1681/ASN.2004060494.CrossRefPubMed
7.
Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, et al: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007, 322 (1): 8-15. 10.1124/jpet.107.119792.CrossRefPubMed
8.
Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006, 21 (8): 2096-2105. 10.1093/ndt/gfl194.CrossRefPubMed
9.
Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002, 110 (6): 835-842.CrossRefPubMedPubMedCentral
10.
Michalik L, Desvergne B, Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004, 4 (1): 61-70. 10.1038/nrc1254.CrossRefPubMed
11.
Yamaguchi K, Lee SH, Eling TE, Baek SJ: A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther. 2006, 5 (5): 1352-1361. 10.1158/1535-7163.MCT-05-0528.CrossRefPubMed
12.
Rosen ED, Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001, 276 (41): 37731-37734.CrossRefPubMed
13.
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995, 83 (5): 803-812. 10.1016/0092-8674(95)90193-0.CrossRefPubMed
14.
Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999, 4 (4): 585-595. 10.1016/S1097-2765(00)80209-9.CrossRefPubMed
15.
Gupta RA, Dubois RN: Controversy: PPARgamma as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2002, 283 (2): G266-269.CrossRefPubMed
16.
Yee LD, Young DC, Rosol TJ, Vanbuskirk AM, Clinton SK: Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J Nutr. 2005, 135 (5): 983-988.PubMed
17.
Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998, 391 (6662): 82-86. 10.1038/34184.CrossRefPubMed
18.
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, et al: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. European journal of pharmacology. 2004, 483 (1): 79-93. 10.1016/j.ejphar.2003.10.056.CrossRefPubMed
19.
Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK: Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol. 2004, 68 (6): 1215-1220. 10.1016/j.bcp.2004.05.038.CrossRefPubMed
20.
Musri MM, Corominola H, Casamitjana R, Gomis R, Parrizas M: Histone H3 lysine 4 dimethylation signals the transcriptional competence of the adiponectin promoter in preadipocytes. J Biol Chem. 2006, 281 (25): 17180-17188. 10.1074/jbc.M601295200.CrossRefPubMed
21.
Fu M, Wang C, Zhang X, Pestell RG: Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol. 2004, 68 (6): 1199-1208. 10.1016/j.bcp.2004.05.037.CrossRefPubMed
22.
23.
Mishra SK, Mandal M, Mazumdar A, Kumar R: Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. FEBS Lett. 2001, 507 (1): 88-94. 10.1016/S0014-5793(01)02951-9.CrossRefPubMed
24.
Whitsett T, Carpenter M, Lamartiniere CA: Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. Journal of carcinogenesis. 2006, 5: 15-10.1186/1477-3163-5-15.CrossRefPubMedPubMedCentral
25.
Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A: Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res. 2008, 42 (4): 397-404. 10.1080/10715760801998646.CrossRefPubMed
26.
Stuhr LE, Iversen VV, Straume O, Maehle BO, Reed RK: Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer letters. 2004, 210 (1): 35-40. 10.1016/j.canlet.2004.02.012.CrossRefPubMed
27.
Tikoo K, Tripathi DN, Kabra DG, Sharma V, Gaikwad AB: Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett. 2007, 581 (5): 1071-1078. 10.1016/j.febslet.2007.02.006.CrossRefPubMed
28.
Tikoo K, Bhatt DK, Gaikwad AB, Sharma V, Kabra DG: Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Lett. 2007, 581 (10): 2027-2035. 10.1016/j.febslet.2007.04.036.CrossRefPubMed
29.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
30.
De Zutter GS, Davis RJ: Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA. 2001, 98 (11): 6168-6173. 10.1073/pnas.111027698.CrossRefPubMedPubMedCentral
31.
Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res. 2000, 256 (1): 34-41. 10.1006/excr.2000.4836.CrossRefPubMed
32.
Hui L, Bakiri L, Stepniak E, Wagner EF: p38alpha: A Suppressor of Cell Proliferation and Tumorigenesis. Cell Cycle. 2007, 6 (20):
33.
Liao Y, Hung MC: Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol. 2003, 23 (19): 6836-6848. 10.1128/MCB.23.19.6836-6848.2003.CrossRefPubMedPubMedCentral
34.
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998, 1 (3): 465-470. 10.1016/S1097-2765(00)80047-7.CrossRefPubMed
35.
Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, et al: Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003, 23 (17): 6159-6173. 10.1128/MCB.23.17.6159-6173.2003.CrossRefPubMedPubMedCentral
36.
Fu M, Wang C, Wang J, Zafonte BT, Lisanti MP, Pestell RG: Acetylation in hormone signaling and the cell cycle. Cytokine & growth factor reviews. 2002, 13 (3): 259-276. 10.1016/S1359-6101(02)00003-5.CrossRef
37.
Shibayama Y, Kawachi A, Onimaru S, Tokunaga J, Ikeda R, Nishida K, Kuchiiwa S, Nakagawa S, Takamura N, Motoya T, et al: Effect of pre-treatment with St John's Wort on nephrotoxicity of cisplatin in rats. Life Sci. 2007, 81 (2): 103-108. 10.1016/j.lfs.2007.04.025.CrossRefPubMed
38.
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: the second decade. Cell. 1995, 83 (6): 835-839. 10.1016/0092-8674(95)90199-X.CrossRefPubMed
39.
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992, 358 (6389): 771-774. 10.1038/358771a0.CrossRefPubMed
40.
Na HK, Surh YJ: Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochemical pharmacology. 2003, 66 (8): 1381-1391. 10.1016/S0006-2952(03)00488-X.CrossRefPubMed
41.
Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer research. 2000, 60 (6): 1604-1608.PubMed
42.
Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S: Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer research. 2003, 63 (5): 958-964.PubMed
43.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
Metadata
Title
Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats
Authors
Kulbhushan Tikoo
Parveen Kumar
Jeena Gupta
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-107

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma

Research article

Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma

Research article

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

Research article

Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases

Research article

Differential baseline and response profile to IFN-γ gene transduction of IL-6/IL-6 receptor-α secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture

Research article

Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits